Xolve seeks funds for scale up; attempts to avoid tribulations of carbon nanomaterial predecessors by focusing on masterbatch sales

We recently caught up with graphene nanoplatelet (GNP) dispersion developer Xolve (see the October 22, 2012 LRMJ) CEO John Biondi to discuss the firm's latest financing activities. John said the company is working on two rounds concurrently at the moment. First, it has secured a low-interest deve...

This research is archived and therefore no longer available. For further assistance please contact your Customer Success Manager or email ClientEngagementTeam@luxresearchinc.com. Thank you!

Related Research

Breakthrough Energy Ventures raises second $1 billion fund, targeting 40 to 50 startups with emphasis on hard-to-decarbonize sectors

News Commentary | January 19, 2021

Since its first fund in 2015, BEV has invested in 30 startups across a range of technology areas. Key startups backed by BEV include Boston Metal, CarbonCure, Pivot Bio, Form Energy, and Nature's Fynd. With the recent SPAC craze driving up valuations of startups in the cleantech space, there is ... Not part of subscription

Solidia raises $78 million and names new CEO – will these developments finally lead to commercialization?

News Commentary | May 06, 2021

Solidia Technologies has a new CEO, Bryan Kalbfleisch, along with $78 million more in funding from Imperative Ventures, Zero Carbon Partners, and Breakthrough Energy Ventures, along with existing investors. The company has a promising technology, but the lack of scale‑up and commercialization ... Not part of subscription

Ginkgo Bioworks to go public via $17.5 billion SPAC deal

News Commentary | May 13, 2021

Backed by Harry Sloan and Jeff Sagansky, this merger with Soaring Eagle Acquisition will give Ginkgo a pre‑money equity valuation of $15 billion, with an additional $2.5 billion for the combined entity – one of the biggest SPAC deals in recent times. This news comes on the heels of Zymergen's IPO ... To read more, click here.